| Intervention (drug/device/gene therapy) | Indication within GEFS+ spectrum | Mechanism/rationale | Evidence type | Key quantitative details (enrollment, endpoints, yields) | MAXO term suggestions | Source (context IDs) |
|---|---|---|---|---|---|---|
| ETX101 (rAAV9-delivered gene therapy; one-time ICV administration) | SCN1A-positive Dravet syndrome within the SCN1A/GEFS+ spectrum; ClinicalTrials.gov indexing includes “Generalized Epilepsy With Febrile Seizures Plus, Type 2” | Engineered transcription factor (eTFSCN1A) under a GABAergic regulatory element (reGABA) designed to increase SCN1A transcription in inhibitory neurons | Interventional clinical trial, Phase 1/2 | NCT05419492; recruiting; estimated enrollment 47; age cohorts include ≥6 to <36 months, ≥48 months to <18 years, and ≥6 to <48 months; primary efficacy endpoint is percent change in monthly countable seizure frequency from pre-dose baseline to Weeks 5–52; safety endpoints include DLTs, AEs/SAEs, Grade ≥3 AEs, hospitalizations, and overall survival; start date 2024-05-14; primary completion estimated 2028-01 (pqac-00000026, pqac-00000027) | MAXO:gene therapy; MAXO:intracerebroventricular administration; MAXO:seizure monitoring | (pqac-00000026, pqac-00000027) |
| ETX101 (Australia-only study) | SCN1A-positive Dravet syndrome within the broader GEFS+/SCN1A spectrum | Same SCN1A upregulation strategy as above; regional safety/efficacy implementation | Interventional clinical trial, Phase 1/2 | NCT06112275; ACTIVE_NOT_RECRUITING; enrollment 4 participants reported in trial search output; Australian study arm/site implementation (clinical-trial retrieval output) | MAXO:gene therapy; MAXO:intracerebroventricular administration | (pqac-00000026) |
| Targeted next-generation sequencing (TNGS) epilepsy panel | GEFS+ as a Mendelian pediatric epilepsy syndrome with a limited set of recurrent major genes | First-step molecular diagnosis to identify pathogenic/likely pathogenic variants in major epilepsy genes and support syndrome-specific management | Observational cohort / diagnostic implementation study | In a monocentric cohort of 1000 pediatric-onset epilepsies, overall panel yield was 31%; GEFS+ subgroup (n=62) had 16% diagnostic yield; authors conclude TNGS is an effective first-step screen for syndromes associated with one or a few major genes and explicitly include GEFS+ (pqac-00000006, pqac-00000016, pqac-00000031) | MAXO:genetic testing; MAXO:targeted gene panel sequencing; MAXO:molecular diagnosis | (pqac-00000006, pqac-00000016, pqac-00000031) |
| Whole-exome sequencing / whole-genome sequencing (WES/WGS) | GEFS+ or unresolved SCN1A-spectrum epilepsies after negative panel testing; broader pediatric epilepsy diagnostics | Second-tier or first-tier genomic testing to improve diagnosis when targeted panels are negative or phenotype is genetically heterogeneous | Observational cohort / diagnostic strategy study | Barcia et al. recommend WES/WGS as a second step for groups with likely Mendelian inheritance including GEFS+ after panel testing; in a separate pediatric epilepsy cohort of 733 families, WGS/WES achieved a molecular diagnosis in 278/733 (37.9%), demonstrating utility of genome-scale testing in clinical epilepsy practice (pqac-00000006, pqac-00000016) | MAXO:whole exome sequencing; MAXO:whole genome sequencing; MAXO:molecular diagnosis | (pqac-00000006, pqac-00000016) |
| Gene-directed therapy decisions after NGS | SCN1A-related epilepsy phenotypes overlapping GEFS+/Dravet spectrum | Molecular diagnosis can alter treatment choices and counseling even when intervention is not syndrome-exclusive | Observational precision-medicine study | In a 55-child epilepsy cohort analyzed by clinical-exome/WES, diagnostic yield was 50.9% (28/55); 46.4% of diagnosed cases had novel variants; gene-directed therapy decisions were made for 11 children, including 4 carrying novel SCN1A variants (pqac-00000029) | MAXO:precision medicine intervention; MAXO:genetic testing; MAXO:treatment planning | (pqac-00000029) |
| Cannabidiol add-on therapy | Severe pediatric epilepsies at the severe end of the GEFS+ spectrum (especially Dravet syndrome rather than typical uncomplicated GEFS+) | Broad antiseizure and neuromodulatory effects; cited in GEFS+-focused translational review as part of current therapeutic landscape | Review summarizing randomized and real-world clinical evidence | Recent GEFS+/GABRG2 review cites randomized and real-world data for cannabidiol in severe pediatric epilepsy, but no GEFS+-specific quantitative efficacy estimate was retrieved in current evidence (pqac-00000025) | MAXO:cannabidiol therapy; MAXO:antiseizure medication administration | (pqac-00000025) |
| SAHA/vorinostat (HDAC inhibitor) | Experimental GABRG2-related GEFS+ / inhibitory synaptic dysfunction | Corrects inhibitory synaptic deficits associated with γ2 missense mutation effects in preclinical systems; mechanistically targets receptor trafficking/synaptic dysfunction | Preclinical / translational review | GEFS+/GABRG2 review reports that SAHA corrected inhibitory synaptic deficits from γ2 missense mutations in vitro/experimental models; no human trial data retrieved for GEFS+ (pqac-00000025) | MAXO:histone deacetylase inhibitor therapy; MAXO:experimental therapy | (pqac-00000025) |
| Dimethyl fumarate repurposing | Experimental disease-modification concept for genetic epilepsy/GEFS+ mechanisms | Repurposing strategy proposed for pathway modulation in genetic epilepsies | Preclinical/translational review | Mentioned as a repurposing approach in the 2024 GABRG2/GEFS+ review; no GEFS+-specific clinical efficacy metrics retrieved (pqac-00000025) | MAXO:drug repurposing; MAXO:experimental therapy | (pqac-00000025) |
| Hyperthermia seizure-model screening with TRPV4 or NMDA antagonists | Experimental fever-triggered SCN1A/GEFS+ mechanisms | Preclinical screening platform for heat-induced seizures relevant to GEFS+; targets fever-provoked excitability | Preclinical zebrafish/mouse-model review | Hyperthermia-induced zebrafish seizure model is rapid, reversible, and non-lethal; TRPV4 antagonists and NMDA receptor antagonists prevented seizures in the model, while GABA reuptake inhibitors did not; supports mechanism-based drug discovery rather than current standard care (pqac-00000028) | MAXO:preclinical drug screening; MAXO:temperature-trigger avoidance not applicable; MAXO:experimental therapy | (pqac-00000028) |
| Anti-IL-6 / STAT3–IL-6 pathway inhibition | Experimental inflammatory modulation for GEFS+-like febrile seizure susceptibility | Seizures activate glia and inflammatory pathways; IL-6 pathway blockade suppressed seizures in model systems | Preclinical review | Intranasal IL-6 increased seizure severity in GEFS+ mice, whereas STAT3-IL-6 pathway inhibition (Stattic) or anti-IL-6 monoclonal antibody significantly suppressed seizures; no human GEFS+ trial data retrieved (pqac-00000028) | MAXO:anti-inflammatory therapy; MAXO:monoclonal antibody therapy; MAXO:experimental therapy | (pqac-00000028) |


*Table: This table summarizes current clinical and translational applications relevant to GEFS+ and the SCN1A-related epilepsy spectrum, including diagnostic strategies, emerging gene therapy trials, and preclinical mechanism-based treatments. It is useful for linking interventions to evidence type, quantitative details, and MAXO-style action annotations.*